Author/Authors :
Kim، نويسنده , , Byeong-Keuk and Hong، نويسنده , , Myeong-Ki and Shin، نويسنده , , Dong-Ho and Nam، نويسنده , , Chung-Mo and Kim، نويسنده , , Jung-Sun and Ko، نويسنده , , Young-Guk and Choi، نويسنده , , Donghoon and Kang، نويسنده , , Tae-Soo and Park، نويسنده , , Byoung-Eun and Kang، نويسنده , , Woong-Chol and Lee، نويسنده , , Seung Hwan and Yoon، نويسنده , , Jung-Han and Hong، نويسنده , , Bum-Kee and Kwon، نويسنده , , Hyuck-Moon and Jang، نويسنده , , Yangsoo، نويسنده ,
Abstract :
Objectives
al of this study was to evaluate shorter duration (3 months) dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation.
ound
have been few published reports of prospective randomized clinical studies comparing the safety and efficacy of shorter duration DAPT after DES implantation.
s
domly assigned 2,117 patients with coronary artery stenosis into 2 groups according to DAPT duration and stent type: 3-month DAPT following Endeavor zotarolimus-eluting stent (E-ZES) implantation (E-ZES+3-month DAPT, n = 1,059) versus 12-month DAPT following the other DES implantation (standard therapy, n = 1,058). We hypothesized that the E-ZES+3-month DAPT would be noninferior to the standard therapy for the primary composite endpoint (cardiovascular death, myocardial infarction, stent thrombosis, target\vessel revascularization, or bleeding) at 1 year.
s
imary endpoint occurred in 40 (4.7%) patients assigned to E-ZES+3-month DAPT compared with 41 (4.7%) patients assigned to the standard therapy (difference: 0.0%; 95% confidence interval [CI]: −2.5 to 2.5; p = 0.84; p < 0.001 for noninferiority). The composite rates of any death, myocardial infarction, or stent thrombosis were 0.8% and 1.3%, respectively (difference: −0.5%; 95% CI: −1.5 to 0.5; p = 0.48). The rates of stent thrombosis were 0.2% and 0.3%, respectively (difference: −0.1%; 95% CI: −0.5 to 0.3; p = 0.65) without its further occurrence after cessation of clopidogrel in the E-ZES+3-month DAPT group. The rates of target vessel revascularization were 3.9% and 3.7%, respectively (difference: 0.2%; 95% CI: −2.3 to 2.6; p = 0.70).
sions
3-month DAPT was noninferior to the standard therapy with respect to the occurrence of the primary endpoint. (REal Safety and Efficacy of a 3-month dual antiplatelet Therapy following E-ZES implantation [RESET]; NCT01145079)
